Search

Objectives: Assessment of contrast agent kinetics in contrast-enhanced MRI (CE-MRI) with gadolinium-containing contrast agents offers the opportunity to predict breast lesion malignancy. The goal of our study was to determine if similar patterns exist for spectral contrast-enhanced digital breast tomosynthesis (CE-DBT) using an iodinated contrast agent., Methods: The protocol of our prospective study was approved by the relevant institutional review board and the German Federal Office for Radiation Protection. All patients provided written informed consent. We included 21 women with a mean age of 62.4 years. All underwent ultrasound-guided biopsy of a suspect breast lesion, spectral CE-DBT and CE-MRI. For every breast lesion, contrast agent kinetics was assessed by signal intensity-time curves for spectral CE-DBT and CE-MRI. Statistical comparison used Cohen's kappa and Spearman's rho test., Results: Spearman's rho of 0.49 showed significant (P = 0.036) correlation regarding the contrast agent kinetics in signal intensity-time curves for spectral CE-DBT and CE-MRI. Cohen's kappa indicated moderate agreement (kappa = 0.438)., Conclusion: There is a statistically significant correlation between contrast agent kinetics in the signal intensity-time curves for spectral CE-DBT and CE-MRI. Observing intralesional contrast agent kinetics in spectral CE-DBT may aid evaluation of malignant breast lesions., Key Points: • Contrast agent kinetics can be assessed using spectral digital breast tomosynthesis (DBT). • Contrast agent kinetics patterns in spectral DBT are similar to those in contrast-enhanced MRI. • Multiple contrast enhancement for spectral DBT gives additional diagnostic information.

The article presents a study regarding the effectiveness of uterine artery embolization (UAE) as treatment for symptomatic uterine leiomyomas in women. The study used magnetic resonance imaging (MRI) to evaluate the condition of 38 women after having UAE. It adds that younger women with incomplete fibroid infarction were found to have higher risk to experience treatment failure (TF) .